A case series of 10 patients with metastatic uveal melanoma suggests that pembrolizumab (Keytruda, Merck)is associated with a mean length of progression-free survival of 18 weeks (Melanoma Res 2016 Feb 4. [Epub ahead of print], PMID: 26848796).
Metastatic uveal melanoma is rare, the investigators wrote, with five to seven diagnoses per 1 million people annually in the United States. They noted that patients with this type of melanoma historically have lower response rates to traditional